Head-To-Head Contrast: iTeos Therapeutics (NASDAQ:ITOS) & Invizyne Technologies (NASDAQ:IZTC)

Invizyne Technologies (NASDAQ:IZTC) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Invizyne Technologies and iTeos Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
iTeos Therapeutics	$35.00 million	7.10	-$112.64 million	($3.31)	-1.97

Invizyne Technologies has higher earnings, but lower revenue than iTeos Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings for Invizyne Technologies and iTeos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0	0	0	0	0.00
iTeos Therapeutics	0	0	4	0	3.00

iTeos Therapeutics has a consensus price target of $25.75, suggesting a potential upside of 295.55%. Given iTeos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Invizyne Technologies.

Insider & Institutional Ownership

97.2% of iTeos Therapeutics shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Invizyne Technologies and iTeos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
iTeos Therapeutics	N/A	-20.11%	-17.50%

Summary

iTeos Therapeutics beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.